- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02389595
Selection of a Protective T Cell-based HIV-1/FIV Vaccine
Selection of a Protective T Cell-based HIV-1/FIV Vaccine Devoid of Viral Enhancing Epitopes
The purpose of this research study is to develop a vaccine against Human immunodeficiency virus (HIV), a disease that causes AIDS in people,. The investigator will be looking at viruses similar to HIV in animals. Since these viruses are very similar to HIV, the blood from humans who have been exposed to HIV will be tested to see if the immune system will recognize the HIV and prevent infection.
HIV targets the immune system by attacking certain T cells called CD4+ T cells. There are parts on the AIDS viruses that help the virus infect these cells and other parts that help the immune system prevent viral infection by activating protective T-cells that fight HIV. Different T-cell populations are very important in most vaccines as they act as "effectors" that work as part of the immune system to recognize and fight off HIV infection. When effector T cells are activated by appropriate "protective" part(s) of the virus they either block HIV from reproducing or kill HIV infected cells. By finding these common protective parts of each of these human and animal AIDS viruses, the investigator hopes to make a vaccine that helps the immune system prevent HIV infection by avoiding parts that attack CD4+ T cells and may worsen HIV infection and selecting for parts that stimulate effector T cells that fight HIV infection.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Janet K Yamamoto, PhD
- Phone Number: 352-294-4145
- Email: yamamoto@ufl.edu
Study Contact Backup
- Name: Alek Aranyos
- Phone Number: 352-294-4196
- Email: aaranyos1@ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
Jacksonville, Florida, United States, 32209
- UF Center for AIDS Research Education and Service
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female subjects between 18 and 65 years old who are HIV positive
Exclusion Criteria:
- Persons with other immune diseases that would result in autoimmunity or aberrant immune responses (such as subjects who have undergone chemotherapy within the past year).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
HIV positive subjects
This group will provide a blood sample.
|
This group will provide a blood sample.
|
Non-infected control subjects
This group consist of de-identified blood samples from a commercial source.
|
This group will be de-identified blood samples from a commercial source.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
T cell proliferation in response to viral epitopes
Time Frame: 120 hours (5 days)
|
120 hours (5 days)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cytokine production in response to viral epitopes
Time Frame: 24 hours (1 day)
|
24 hours (1 day)
|
Cytotoxin production in response to viral epitopes
Time Frame: 8 hours
|
8 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Janet K Yamamoto, PhD, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on HIV positive subjects
-
Walter Sisulu UniversityMedical University of Graz; Nelson Mandela Academic Hospital; Umtata General...Not yet recruitingIn Utero Drug ExposureSouth Africa
-
Medical University of GrazLagos State University; Walter Sisulu University; Management Sciences for Health and other collaboratorsEnrolling by invitationCovid19 | Hiv | ARTNigeria, South Africa
-
University of California, Los AngelesApait Health CenterRecruitingSelf-managementUnited States
-
University of GuadalajaraHospital Civil de GuadalajaraCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic Obstructive
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Wellcome Trust Liverpool Glasgow Centre for Global...Professor David Lalloo; Professor Hamish Simpson; Professor William J Harrison; Professor Sithombo MaqungoUnknownFracture Healing in HIV-positive PatientsSouth Africa
-
Universidade Federal de Sao CarlosUniversidade Metodista de PiracicabaCompleted
-
Buddhist Tzu Chi General HospitalRecruitingIrritable Bowel Syndrome | Functional Gastrointestinal Disorders | Healthy Subjects | Laryngopharyngeal RefluxTaiwan
-
Ascension St. VincentTerminated